References
- Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front Pharmacol. 2014;5:146. doi: 10.3389/fphar.2014.00146
- Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102.
- Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307–317.
- Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050–4058.
- Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97–100.
- Duff K. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:713.
- Medina M, Avila J. The need for better ad animal models. Front Pharmacol. 2014;5:227. doi: 10.3389/fphar.2014.00227
- Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421.
- Coelho DS, Schwartz S, Merino MM, et al. Culling less fit neurons protects against amyloid-β-induced brain damage and cognitive and motor decline. Cell Rep. 2018;25:3661–3673.e3.
- Rinne JO. Nigral degeneration in Parkinson’s disease in relation to clinical features. Acta Neurol Scand Suppl. 1991;136:87–90.
- Schapira AH. Pathogenesis of Parkinson’s disease. Baillieres Clin Neurol. 1997;6:15–36.
- Bano D, Zanetti F, Mende Y, et al. Neurodegenerative processes in Huntington’s disease. Cell Death Dis. 2011;2:e228–e228.
- Duchen MR. Mitochondria, calcium-dependent neuronal death and neurodegenerative disease. Pflügers Arch Eur J Physiol. 2012;464:111–121.
- Navarro G, Borroto-Escuela D, Angelats E, et al. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Relevance for Alzheimer’s disease and levo-dopa-induced dyskinesia. Brain Behav Immun. 2008;67:139–151.
- Franco R, Navarro G. Adenosine A2A receptor antagonists in neurodegenerative diseases: huge potential and huge challenges. Front Psychiatry. 2018;9:68. doi: 10.3389/fpsyt.2018.00068.
- Horgusluoglu-Moloch E, Nho K, Risacher SL, et al. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2017;60:92–103.
- Mungenast AE, Siegert S, Tsai LH. Modeling Alzheimer’s disease with human induced pluripotent stem (iPS) cells. Mol Cell Neurosci. 2016;73:13–31.
- Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease. Drugs Aging. 2001;18:797–806.
- Kim IY, O’Reilly ÉJ, Hughes KC, et al. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. 2018;90:e1646–e1653.
- Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism. J Neurosci. 2010;30:5525–5532.
- Zamarbide M, Gil-Bea FJ, Bannenberg P, et al. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer’s disease model mice. Sci Rep. 2018;8(1–13):6434.
- Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the mini-mental state exam scores of older women: findings from the nun study. J Am Geriatr Soc. 1996;44:675–681.